Evidence map›Paper›PMID 42103495›Full record

ReviewTrends in cancer2026

Bioengineered systems to exploit tumor microenvironment metabolism.

Christine Sanganoo, Ilaria Caturegli, Zachary Mattes, Jordan Ryan, Wilson W Wong, Mark W Grinstaff

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christine SanganooDepartment of Pharmacology, Physiology & Biophysics, Chobanian and Avedisian School of Medicine, 700 Albany St W302, Boston, MA 02215, USA.
Ilaria CaturegliDivision of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA.
Zachary MattesDepartment of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA.
Jordan RyanDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, United States.
Wilson W WongDepartment of Biomedical Engineering, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA. Electronic address: wilwong@bu.edu.
Mark W GrinstaffDepartment of Pharmacology, Physiology & Biophysics, Chobanian and Avedisian School of Medicine, 700 Albany St W302, Boston, MA 02215, USA; Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA; Department of Biomedical Engineering, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA. Electronic address: mgrin@bu.edu.

Funding

Synthetic toolkit for precision gene expression control and signal processing in mammalian cellsR01EB029483 · NIBIB · HARVARD UNIVERSITY · PI Ahmad Samir Khalil · 2020 to 2026
$5.0M
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue SarcomasR01CA272637 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Yolonda L Colson, MARK W. GRINSTAFF · 2022 to 2026
$3.5M
Precise tumor targeting with logic CAR circuitsU01CA265713 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2021 to 2025
$2.5M
NCI NIH HHS R01 CA272637NCI NIH HHS U01 CA265713NIBIB NIH HHS R01 EB029483
6 · The paper itself

Abstract

Our understanding of cancer metabolism has afforded the opportunity to develop therapies specific to tumor metabolic dysregulation. While molecular therapeutics targeting cancer metabolism have found success in the clinic, bioengineering approaches are nascent. Here, we describe key metabolic pathways and their genetic dysregulations in the tumor microenvironment (TME) that are ripe for intervention. We examine bioengineered biomaterial and cellular systems that harness the metabolic and immune landscape of the TME to target metabolic dependencies of tumor growth. These therapeutic strategies include, for example, preventing the uptake of essential metabolites, delivering metabolic inhibitors, and restoring an immunostimulating environment. With a focus toward clinical applications and tolerability, we identify key limitations and conclude with future directions.

Indexed as

BioengineeringNeoplasmsTumor MicroenvironmentAnimalsAntineoplastic AgentsBiocompatible MaterialsHumansMetabolic Networks and PathwaysMetabolic ReprogrammingAntineoplastic AgentsBiocompatible Materialsantimetabolite deliverybiomaterialscancer metabolismimmunosuppressive metabolite modulationtumor microenvironment

Identifiers

PMID42103495
PMCPMC13533483

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.